Literature DB >> 11061522

Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients.

L Lazar1, O Kalter-Leibovici, A Pertzelan, N Weintrob, Z Josefsberg, M Phillip.   

Abstract

The course of Graves' thyrotoxicosis in 7 prepubertal children (6.4+/-2.4 yr) was compared with that in 21 pubertal (12.5+/-1.1 yr) and 12 postpubertal (16.2+/-0.84 yr) patients. In the prepubertal group the main complaints were weight loss and frequent bowel movements (86%), whereas typical symptoms (irritability, palpitations, heat intolerance, and neck lump) occurred significantly less often (P < 0.01). The most prominent manifestation at diagnosis was accelerated growth and bone maturation: their height SD score was significantly greater than that of the pubertal and postpubertal patients (2.6+/-0.7 us. 0.15+/-0.65 and 0.15+/-0.9, respectively, P < 0.001), and their bone age to chronological age ratio was 1.39+/-0.35 compared with 0.98+/-0.06 in the pubertal children (P = 0.02). T3 levels were also significantly higher than in the other two groups (9.9+/-2.9 nmol/L vs. 6.32+/-1.9 nmol/L and 6.02+/-2.0 nmol/L, P = 0.01). All patients were initially prescribed antithyroid drugs (ATDs). Overall, adverse reactions to ATDs occurred in 35%, with a higher rate among the prepubertal children (71%) than the pubertal (28%) and postpubertal (25%) patients (P = 0.08). Major adverse reactions were noted in two children, both prepubertal. Remission was achieved in 10 patients (28%). Although the rate of remission did not differ among the three groups, time to remission tended to be longer in the prepubertal children (P = 0.09). In conclusion, thyrotoxicosis has an atypical presentation and more severe course in prepubertal children. Considering their adverse reactions to ATD, overall low remission rate, and long period to remission, definitive treatment should be considered earlier in this age group.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11061522     DOI: 10.1210/jcem.85.10.6922

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  29 in total

Review 1.  Radioiodine treatment for pediatric hyperthyroid Grave's disease.

Authors:  Ma Chao; Xie Jiawei; Wang Guoming; Liu Jianbin; Liu Wanxia; Al Driedger; Zuo Shuyao; Zhang Qin
Journal:  Eur J Pediatr       Date:  2009-05-07       Impact factor: 3.183

2.  Serendipitous identification of Graves' disease in identical twins with polydipsia.

Authors:  Andrea K Goldyn; Erica A Eugster; Todd D Nebesio
Journal:  J Pediatr Endocrinol Metab       Date:  2010-12       Impact factor: 1.634

3.  Juvenile Graves' disease with opthalmopathy, lymphadenopathy, accelerated growth and congestive cardiac failure.

Authors:  M K Dutta; Abhay Gundgurthi; M K Garg; N Kotwal
Journal:  Indian J Pediatr       Date:  2011-06-25       Impact factor: 1.967

4.  Detours on the road to diagnosis of Graves disease.

Authors:  Emily K Sims; Erica A Eugster; Todd D Nebesio
Journal:  Clin Pediatr (Phila)       Date:  2011-08-25       Impact factor: 1.168

5.  Normalization of cortical bone density in children and adolescents with hyperthyroidism treated with antithyroid medication.

Authors:  N Numbenjapon; G Costin; P Pitukcheewanont
Journal:  Osteoporos Int       Date:  2011-12-21       Impact factor: 4.507

6.  Adverse events associated with methimazole therapy of graves' disease in children.

Authors:  Scott A Rivkees; Kerry Stephenson; Catherine Dinauer
Journal:  Int J Pediatr Endocrinol       Date:  2010-03-07

7.  Hyperthyroidism Presenting With Pathologic Fractures.

Authors:  Margaret D Sarezky; Daniel J Corwin; Victor S Harrison; Cynthia Jacobstein
Journal:  Pediatrics       Date:  2016-01-08       Impact factor: 7.124

Review 8.  Juvenile thyrotoxicosis; can we do better?

Authors:  G Birrell; T Cheetham
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

9.  Clinical and endocrine features and long-term outcome of Graves' disease in early childhood.

Authors:  A T Bossowski; V Reddy; L A Perry; L B Johnston; K Banerjee; J C Blair; M O Savage
Journal:  J Endocrinol Invest       Date:  2007-05       Impact factor: 4.256

10.  Propylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use.

Authors:  Scott A Rivkees; Donald R Mattison
Journal:  Int J Pediatr Endocrinol       Date:  2009-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.